These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 17574073)

  • 41. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
    Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A; Li Y; Forastiere A
    Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
    ; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
    Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
    Moore KN; Tian C; McMeekin DS; Thigpen JT; Randall ME; Gallion HH
    Cancer; 2010 Dec; 116(23):5407-14. PubMed ID: 20737572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
    J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
    Honma H; Sagae S; Terasawa K; Tanaka R; Chida M; Mizumoto H; Ishioka S; Saito T; Kudo R
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):549-53. PubMed ID: 15114698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
    Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
    Hogberg T
    Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study.
    Rose PG; Ali S; Whitney CW; Lanciano R; Stehman FB
    Gynecol Oncol; 2011 Jun; 121(3):542-5. PubMed ID: 21420157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
    J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.
    Sovak MA; Hensley ML; Dupont J; Ishill N; Alektiar KM; Abu-Rustum N; Barakat R; Chi DS; Sabbatini P; Spriggs DR; Aghajanian C
    Gynecol Oncol; 2006 Nov; 103(2):451-7. PubMed ID: 16677690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
    Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
    Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effects of postoperative chemotherapy on the prognosis of patients with high-risk early stage endometrial cancer].
    Wen HW; Tian F; Ma L; Liao QP
    Zhonghua Fu Chan Ke Za Zhi; 2009 Mar; 44(3):196-9. PubMed ID: 19570445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
    Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
    Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients.
    Bruzzone M; Miglietta L; Franzone P; Gadducci A; Boccardo F
    Gynecol Oncol; 2004 May; 93(2):345-52. PubMed ID: 15099944
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current treatment options for endometrial cancer.
    Santin AD; Bellone S; O'Brien TJ; Pecorelli S; Cannon MJ; Roman JJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):679-89. PubMed ID: 15270671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
    Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
    Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
    Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
    Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.